Commercial research in the UK’s National Health Service may involve the use of taxpayer-funded resources to support business objectives but it brings multiple benefits beyond swelling pharmaceutical company margins, argue stakeholders from within the service, medical research charities, government and the National Institute for Health Research (NIHR).